by Elena Iemma | May 16, 2023 | News
EpiVax is celebrating 25 years of innovative immunoinformatics tool development. The company’s mission is to improve the safety and efficacy of vaccines and protein therapeutics, while working to improve human health everywhere. 1998 EpiVax...
by Elena Iemma | Apr 4, 2023 | Events
Thank you to everyone who participated in the 9th annual Amsterdam Immunogenicity and Tolerance Seminar! The day would not have been such a success without you. Check out these photos from the event. A special thanks to the Seminar organizing committee: Corine...
by Elena Iemma | Nov 30, 2021 | News
PROVIDENCE, RI, November 30, 2021 /PRNewswire/ — Today EpiVax, Inc. (“EpiVax”) confirmed that the company’s EPV-CoV-19 vaccine epitope sequences are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc....
by Elena Iemma | Sep 10, 2021 | Events
EpiVax participated in the 2021 International Society for Vaccines (ISV) Annual Virtual Congress September 13-15, 2021. The 2021 Congress was a busy one, it’s been a difficult but innovative period for the vaccine development community. Multiple EpiVax...
by Elena Iemma | May 13, 2021 | News
PROVIDENCE, RI, May 13, 2021 /PRNewswire/ — EpiVax Therapeutics, Inc. (“EVT”) announces the publication “Multi‑step screening of neoantigens’ HLA and TCR‑interfaces improves prediction of survival” in Scientific Reports. This study demonstrates a superior method...
